648 related articles for article (PubMed ID: 31732444)
21. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
22. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
Kotwani P; Terdiman J; Lewin S
J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
[TBL] [Abstract][Full Text] [Related]
23. Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.
Gilmore R; Hilley P; Srinivasan A; Choy M; De Cruz P
J Crohns Colitis; 2022 Jan; 16(1):166-168. PubMed ID: 34159363
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
[TBL] [Abstract][Full Text] [Related]
25. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
Molander P; Kosunen M; Eronen H; Tillonen J; Käräjämäki A; Heikkinen M; Punkkinen J; Mattila R; Toppila I; Hölsä O; Kalpala K; Henrohn D; Af Björkesten CG
Scand J Gastroenterol; 2024 Apr; 59(4):425-432. PubMed ID: 38156792
[TBL] [Abstract][Full Text] [Related]
27. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
[TBL] [Abstract][Full Text] [Related]
28. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis.
Nakamura M; Yamamura T; Maeda K; Sawada T; Mizutani Y; Ishikawa E; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Kawashima H; Honda T; Ishigami M; Fujishiro M
Nagoya J Med Sci; 2022 Feb; 84(1):169-179. PubMed ID: 35392018
[TBL] [Abstract][Full Text] [Related]
29. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G
United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274
[TBL] [Abstract][Full Text] [Related]
30. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
31. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
[TBL] [Abstract][Full Text] [Related]
32. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
[TBL] [Abstract][Full Text] [Related]
34. Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study.
Parra-Izquierdo V; Frías-Ordoñez JS; Juliao-Baños F; Cuadros C; Romero Sanchez C; Flórez-Sarmiento C
Gastroenterol Hepatol; 2024; 47(6):582-590. PubMed ID: 37806342
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies.
Macaluso FS; Maida M; Ventimiglia M; Orlando A
Dig Liver Dis; 2022 Feb; 54(2):183-191. PubMed ID: 34011482
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
[TBL] [Abstract][Full Text] [Related]
37. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database.
Seo GH; Jung SH
J Korean Med Sci; 2022 Apr; 37(16):e123. PubMed ID: 35470598
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia.
Hernández Martínez A; Navajas Hernández P; Martín Rodríguez MDM; Lázaro Sáez M; Olmedo Martín R; Núñez Ortiz A; Argüelles Arias F; Fernández Cano MC; Gallardo Sánchez F; Marín Pedrosa S; González García J; Vázquez Morón JM
Rev Esp Enferm Dig; 2022 Sep; 114(9):516-521. PubMed ID: 35000397
[TBL] [Abstract][Full Text] [Related]
39. The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review.
Mpakogiannis K; Fousekis FS; Christodoulou DK; Katsanos KH; Narula N
Dig Liver Dis; 2023 Oct; 55(10):1311-1317. PubMed ID: 37316363
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
